Literature DB >> 11889457

Resistance of Klebsiella pneumoniae strains producing and not producing ESBL (extended-spectrum beta-lactamase) type enzymes to selected non-beta-lactam antibiotics.

Alicja Sekowska1, Grazyna Janicka, Czesław Kłyszejko, Małgorzata Wojda, Marcin Wróblewski, Maria Szymankiewicz.   

Abstract

BACKGROUND: Bacteria of the Klebsiella genus may cause numerous infections in human, which are often treated with beta-lactam antibiotics. The fundamental mechanism of Klebsiella resistance to penicillins or cephalosporins involves the production of enzymes--extended-spectrum beta-lactamases (ESBLs). Because of resistance of many Klebsiella spp. strains to beta-lactams, alternative antibiotic therapy can make use of aminoglycosides and quinolones. MATERIAL/
METHODS: The study analyzed the prevalence of ESBL -type enzymes among 256 Klebsiella pneumoniae strains isolated from various clinical materials collected from patients hospitalized between 1997 and 2000. ESBLs were detected by double-disk synergy test (DDST). The prevalence of strains resistant to selected aminoglycosides (gentamicin, amikacin, netilmicin) and quinolones (ciprofloxacin, norfloxacin, nalidixic acid) in the particular years was analyzed. Drug sensitivity was determined by disk-diffusion method according to the recommendations of the National Reference Center for Microbial Drug Sensitivity.
RESULTS: During the analyzed time interval, a significant increase of the number of K. pneumoniae ESBL(+) strains was noted: in 1997 - 16.5% (14/85) and in 2000 - 40.4% (22/54) (p<0.001). Among the ESBL(+) strains, an increase of the number of strains resistant to the tested antibiotics, except for nalidixic acid, was demonstrated
CONCLUSIONS: A statistically significant increase of multidrug-resistant K. pneumoniae strains, including strains producing ESBLs, was demonstrated in the analyzed material.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11889457

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  4 in total

Review 1.  Extended-spectrum beta-lactamases: a clinical update.

Authors:  David L Paterson; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

2.  ESBLs: A Clear and Present Danger?

Authors:  Rishi H-P Dhillon; John Clark
Journal:  Crit Care Res Pract       Date:  2011-06-06

3.  Extended spectrum beta-lactamases among Gram-negative bacteria of nosocomial origin from an intensive care unit of a tertiary health facility in Tanzania.

Authors:  Faustine Ndugulile; Roland Jureen; Stig Harthug; Willy Urassa; Nina Langeland
Journal:  BMC Infect Dis       Date:  2005-10-15       Impact factor: 3.090

4.  Antibiotic resistance ofKlebsiella pneumoniae through β-arrestin recruitment-induced β-lactamase signaling pathway.

Authors:  Jiang Wei; Yang Wenjie; Liu Ping; Wang Na; Ren Haixia; Zhao Xuequn
Journal:  Exp Ther Med       Date:  2018-01-09       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.